Abstract

Objectives  The *Burkholderia cepacia* complex (Bcc), which was originally thought to be a single species, represents a group of 24 distinct species that are often resistant to multiple antibiotics, and usually known to cause life-threatening pulmonary infections in cystic fibrosis patients. Herein we describe a series of non-respiratory Bcc infections, the risk factors and epidemiologic factors, in addition to the clinical course.

Patients and methods  This is a retrospective chart review of 44 patients with documented *B. cepacia* infections isolated from sites other than the respiratory tract admitted between June 2005 and February 2020 to the American University of Beirut Medical Center (AUBMC), a tertiary referral hospital for Lebanon and the Middle East region. The epidemiological background of these patients, their underlying risk factors, the used antibiotic regimens, and the sensitivities of the *B. cepacia* specimens were collected.

Results  The majority of the Bcc infections (26/44, 59.1%) were hospital-acquired infections. The most common nationality of the patients was Iraqi (18/44, 40.9%), and the most common site of infection was bacteremia (17/44, 38.6%), followed by skin and soft tissues infections (16/44, 36.4%) and vertebral osteomyelitis (8/44, 18.2%). Most of the isolated *B. cepacia* were susceptible to ceftazidime, carbapenems, followed by TMP-SMX. Patients responded well to therapy with good overall outcome.

Conclusions  Bcc can cause infections outside the respiratory tract, mostly as hospital-acquired infections and in immunocompromised patients. Most patients were referred from countries inflicted by wars raising the possibility of a potential role of conflicts which need to be investigated in future studies. Directed therapy according to susceptibility results proved effective in most patients.

Keywords  *Burkholderia cepacia* · Osteomyelitis · Bacteremia · Skin and soft tissue infections

Abbreviations

| Bcc          | *Burkholderia cepacia* Complex |
|--------------|-------------------------------|
| AUBMC        | American university of Beirut medical center |
| TMP-SMX      | Trimethoprim sulfamethoxazole |
| CLSI         | Clinical laboratory and standards institute |
| DD           | Disc diffusion |
| EHR          | Electronic health records |
| SOFA score   | Sequential organ failure assessment score |
| SPSS         | Statistical package for social sciences |
| ICU          | Intensive care unit |
| SSTI         | Skin and soft tissue infections |
| IDSA         | The infectious diseases society of America |
| T5           | Thoracic vertebrae number 5 |
| ASP          | Antimicrobial stewardship program |

Rola Kwayess has contributed equally to this work.

Souha S. Kanj
sk11@aub.edu.lb

1 Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

2 Division of Infectious Diseases, American University of Beirut Medical Center, Riad El Solh, PO Box 11-0236, Beirut 1107 2020, Lebanon

1 Introduction

The *Burkholderia cepacia* complex (Bcc) represents a group of 24 distinct species [1]. These Gram-negative rods are motile, aerobic, glucose non-fermenting organisms, and often resistant to multiple antibiotics. *B. cepacia* is a
common respiratory pathogen in patients with chronic lung disease such as cystic fibrosis [2] but rarely causes community-acquired infections outside the respiratory tract. Organisms of the Bcc are found in natural habitats such as soil and water. Because they can survive in the presence of disinfectants, they act as potential nosocomial infections. Multiple studies suggest that patients with debilitating underlying diseases, those with an indwelling device or those with prolonged intensive care unit stay, are at increased risk of Bcc nosocomial infections [3–5].

Bcc infections are intrinsically resistant to many antimicrobial agents thus limiting the therapeutic options. Although Bcc has been rarely reported as the causative organism of vertebral osteomyelitis, its overall incidence in this location has steadily increased during the past years [6–8]. Some antibiotics such as ceftazidime, carbapenem, trimethoprim-sulfamethoxazole (TMP-SMX), and fluoroquinolones have shown in vitro activities against this bacterium, and some combinations of antibiotics have shown synergy [5].

The rarity of published Bcc infections outside the respiratory tract in the literature highlights the importance of this study where we report the unusual increased number of infections outside the respiratory tract over the past few years at our medical center particularly among patients referred from Syria and Iraq, countries inflicted by wars.

2 Methods

2.1 Study Design and Setting

This study is a retrospective chart review of 44 patients who presented to the American University of Beirut Medical Center (AUBMC), the largest tertiary care center in Lebanon, with documented B. cepacia complex infection at sites other than the respiratory tract reviewed between June 2005 and February 2020. The epidemiological background of these patients, their underlying risk factors and comorbidities, the antibiotic regimens used, the duration of their treatment as well as the sensitivities of the Bcc isolates were reviewed (Table 1).

2.2 Microbiological Data

B. cepacia was identified as per standardized laboratory methods, cultured on MacConkey agar. The antibiotics tested for susceptibility were chosen by the microbiology laboratory at AUBMC as per the yearly updated recommendations of the Clinical Laboratory and Standards Institute (CLSI) [9] and included minocycline, TMP-SMX, meropenem, ceftazidime, with standardized disc diffusion (DD) testing methods. As for ciprofloxacin, aminoglycoside, tigecycline, and piperacillin-tazobactam, they were tested upon physician’s request.

2.3 Clinical Data

The patients’ demographics, comorbidities, smoking status, potential risk factors such as the presence of indwelling catheters at the time of the positive cultures, prior procedures, the use of steroids or any other therapy causing immunosuppression within 30 days prior to the positive cultures were recorded from the electronic health records (EHR).

The type and source of the Bcc infection were identified by reviewing the dates of positive cultures. The antibiotics administered prior to the culture results for other infections as well as the antibiotics administered after the cultures grew Bcc were collected.

2.4 Criteria for Bcc Classification

Hospital acquired infections were defined as infections with an onset of > 48 h since current admission or < 90 days since last hospitalization, while infections occurring as outpatient or < 48 h since current admission were designated as community acquired infections.

Patients with B. cepacia bacteremia as a complication of respiratory infections were excluded.

Patients who had received chemotherapy, immunotherapy, biologic therapy, radiation therapy or steroids within the 30 days prior to their current admission were considered immunosuppressed.

The Pitt bacteremia score [10], the Charlson index score [11], and the SOFA score [12] were calculated for patients with bacteremia.

2.5 Statistical Analysis

The Statistical Package for Social Sciences (SPSS), version 27, was used to perform data entry, management, and analyses. The descriptive of the continuous and categorical variables as means/standard deviations and frequencies/percentages were presented, respectively.

3 Results

3.1 Patients’ Characteristics

The mean age of these 44 patients was 50+/19 years at the time of their Bcc infection and 31 of them (31/44, 70.5%) were male. The most common nationality was Iraqi (18/44, 40.9%), followed by Lebanese (15/44, 34.1%), and Syrian (9/44, 20.5%) nationalities. 65.9% (29/44) of our patients were non-Lebanese residents. Throughout the dates of
### Table 1: Characteristics of patients with *B. cepacia* infection

| Type of Infection         | Age | Sex | Nationality | Hospital Admission | ICU Admission | Infection Acquisition | Treatment and Duration* | Disposition          |
|---------------------------|-----|-----|-------------|--------------------|---------------|-----------------------|------------------------|----------------------|
| Bacteremia                | 73  | M   | L           | Yes                | No            | HAI                   | Carbapenem for 8 days  | Discharged           |
|                           | 59  | M   | L           | Yes                | Yes           | HAI                   | Carbapenem for 10 days |                     |
|                           | 59  | M   | I           | Yes                | No            | HAI                   | Carbapenem for 10 days |                     |
|                           | 34  | M   | S           | Yes                | Yes           | HAI                   | Carbapenem for 14 days |                     |
|                           | 77  | M   | L           | Yes                | No            | HAI                   | Quinolone for 15 days  |                     |
|                           | 53  | F   | L           | Yes                | Yes           | HAI                   | Ceftazidime for 10 days|                     |
|                           | 89  | M   | L           | Yes                | No            | CAI                   | Ceftazidime for 14 days|                     |
|                           | 69  | F   | L           | Yes                | No            | HAI                   | TMP-SMX and Quinolone for 18 days |                     |
|                           | 40  | M   | L           | Yes                | No            | HAI                   | NA                     |                     |
|                           | 70  | F   | S           | Yes                | No            | HAI                   | Ceftazidime and Tetracycline for 10 days |                     |
|                           | 7   | M   | S           | Yes                | Yes           | HAI                   | TMP-SMX for 12 days   |                     |
|                           | 54  | M   | I           | Yes                | Yes           | HAI                   | Ceftazidime and Aminoglycoside for 15 days |                     |
|                           | 43  | M   | I           | Yes                | No            | HAI                   | Aminoglycoside and TMP-SMX for 14 days | Discharged           |
|                           | 69  | M   | I           | Yes                | Yes           | CAI                   | Piperacillin-tazobactam and Vancomycin for 15 days |                     |
|                           | 63  | F   | S           | Yes                | Yes           | HAI                   | Ceftazidime and Quinolone for 37 days |                     |
| Bacteremia + Osteomyelitis| 33  | F   | I           | Yes                | No            | HAI                   | Tetracycline and Rifampin for 21 days | Discharged           |
|                           | 43  | M   | I           | No                 | No            | CAI                   | NA                     | NA                  |
| Osteomyelitis             | 58  | F   | I           | Yes                | No            | HAI                   | Ceftazidime and TMP-SMX for 42 days | Discharged           |
|                           | 28  | F   | I           | Yes                | No            | CAI                   | Ceftazidime for 14 days|                     |
|                           | 99  | M   | NA          | Yes                | No            | HAI                   | Tigecycline and Quinolone for 10 days |                     |
|                           | 56  | F   | S           | No                 | No            | CAI                   | Quinolone              | NA                  |
|                           | 36  | M   | I           | No                 | No            | CAI                   | TMP-SMX for 210 days  |                     |
|                           | 30  | F   | I           | No                 | Yes           | NA                    | Quinolone              | NA                  |
|                           | 40  | M   | I           | No                 | Yes           | CAI                   | Ceftazidime, TMP-SMX, and Quinolone for 28 days |                     |
|                           | 36  | M   | S           | No                 | Yes           | HAI                   | Ceftazidime, Tetracycline, and Quinolone for 60 days |                     |
| Skin/soft tissue          | 25  | M   | L           | No                 | No            | CAI                   | Tigecycline, TMP-SMX, and Quinolone for 7 days | NA                  |
|                           | 22  | M   | L           | Yes                | No            | HAI                   | Ceftazidime, Tigecycline, and Quinolone for 17 days | Discharged           |
|                           | 71  | M   | L           | Yes                | No            | CAI                   | TMP-SMX for 14 days   |                     |
|                           | 31  | M   | L           | No                 | No            | NA                    | NA                     |                     |
|                           | 13  | M   | I           | Yes                | Yes           | HAI                   | Tigecycline for 20 days|                     |
| Abscess                   | 56  | M   | L           | Yes                | No            | HAI                   | Carbapenem            | Discharged           |
|                           | 58  | M   | L           | Yes                | No            | HAI                   | Carbapenem for 12 days|                     |
|                           | 26  | F   | I           | Yes                | Yes           | CAI                   | Ceftazidime for 14 days|                     |
|                           | 56  | M   | I           | Yes                | No            | HAI                   | Carbapenem for 18 days|                     |
| Wound                     | 46  | M   | L           | Yes                | No            | HAI                   | Quinolone and Vancomycin| Discharged           |
|                           | 56  | M   | S           | No                 | No            | NA                    | NA                     |                     |
|                           | 65  | M   | I           | Yes                | No            | CAI                   | Carbapenem            |                     |
the patients’ admissions the percentage of Iraqi and Syrian patients at AUBMC did not exceed 2–3%. Thirty-eight patients (38/44, 86.4%), had a history of malignancy (19/44, 50%) or a history of surgical procedure on the infection site (19/44, 50%). Eight patients (8/44, 18.2%) had atherosclerotic cardiovascular disease, 14 (14/44, 31.8%) were smokers and 7 (7/44, 15.9%) were diabetic. Sixteen patients (16/44, 36.4%) had received antibiotics within the 30 days prior to the isolation of Bcc for other types of infections. The two most commonly used antibiotics were ceftazidime and carbapenems followed by quinolones. Nine patients (9/44, 20.5%) received therapies other than antibiotics within the 30 days prior to their infection, specifically chemotherapy and steroids (Table 2).

### 3.2 Hospital Admissions’ Characteristics

Thirty-three patients (33/44, 75%) were admitted to the hospital at the time they had their positive Bcc culture, with a median length of hospital stay of 8 (5–16.5) days. At the time of the positive culture, 20 of these admitted patients (20/44, 45.5%) had an indwelling catheter and 12 (12/44, 27.3%) were in the ICU, with a median length of ICU stay of 3.5 (2–10.5) days. Thirty-two patients (32/44, 96.9%) were discharged from the hospital, whereas one patient succumbed to his infection.

### 3.3 Burkholderia cepacia Complex Infections’ Characteristics

Almost all the Bcc infections (43/44, 97.7%) were recorded in these patients for the first time, where 26 of them (26/44, 59.1%) were hospital-acquired infections. Multiple sites of Bcc infections were noted, with the most common being central line associated bacteremia (17/44, 38.6%), followed by skin and soft tissue infections (SSTIs) (including ulcers, wounds, and burns) as well as deep seated cysts and abscesses (16/44, 36.4%) and vertebral osteomyelitis (8/44, 18.2%). Four other infection sites were noted and included, ascitic fluid, vitreous fluid, gastric band port, a scalp lesion and biliary fluid, respectively. In the patients with bacteremia, the average Pitt Bacteremia score, SOFA score, and Charlson index score were respectively 1.36 (± 2.678), 3.27 (± 3.349), and 4.40 (± 3.641). Among the eight vertebral osteomyelitis cases, four were located in the lumbar region, three in the cervical region and one at multiple vertebral levels; five of these cases were native vertebral osteomyelitis.

---

**Table 1** (continued)

| Type of Infection | Age | Sex | Nationality | Hospital Admission | ICU Admission | Infection Acquisition | Treatment and Duration* | Disposition |
|-------------------|-----|-----|-------------|-------------------|--------------|----------------------|-------------------------|------------|
| Catheter          | 51  | F   | I           | No                | No           | CAI                  | NA                      | NA         |
|                   | 50  | F   | S           | Yes               | No           | CAI                  | Ceftazidime             | Discharged |
|                   | 53  | M   | S           | Yes               | No           | CAI                  | NA                      | Discharged |
|                   | 56  | M   | L           | Yes               | No           | HAI                  | Ceftazidime             |             |
|                   | 47  | M   | I           | Yes               | No           | CAI                  | TMP-SMX                 |             |
|                   | 49  | M   | I           | Yes               | No           | HAI                  | Quinolone               |             |
|                   | 66  | M   | I           | Yes               | No           | NA                   | Minocycline             | NA         |

*M male, F female, L lebanese, S Syrian, I Iraqi, HAI hospital acquired infection, CAI community acquired infection

*The standard dose for treatment of gram-negative bacteria was used, adjusted to creatinine clearance

**Table 2** Risk factors of patients with *B. cepacia* infections

| Patients’ characteristics | Age | Gender | Nationality | Smoking history | Atherosclerotic cardiovascular disease | Cerebral vascular accident | Chronic kidney disease | Chronic liver disease | Malignancy | Prior surgical history on affected site | History of trauma |
|---------------------------|-----|--------|-------------|-----------------|--------------------------------------|---------------------------|-----------------------|----------------------|-------------|----------------------------------------|------------------|
| Age                       | 50.34 ± 19.048 | Males | Iraqi | 26 (59.1%) | 8 (18.2%) | 3 (6.8%) | 6 (13.6%) | 2 (4.5%) | 19 (43.2%) | 19 (43.2%) | 4 (9.1%) |
| Gender                    | 31 (70.5%) | Females | Lebanese | 15 (34.1%) | | | | | | | |
| Nationality               | 9 (20.5%) | Others | Syrian | 9 (20.5%) | | | | | | | |
| Smoking history           | 13 (29.5%) | Others | Others | 1 (4.5%) | | | | | | | |
| Atherosclerotic cardiovascular disease | 8 (18.2%) | | | | | | | | | | |
| Cerebral vascular accident | 3 (6.8%) | | | | | | | | | | |
| Chronic kidney disease    | 6 (13.6%) | | | | | | | | | | |
| Chronic liver disease     | 2 (4.5%) | | | | | | | | | | |
| Malignancy                | 19 (43.2%) | | | | | | | | | | |
| Prior surgical history on affected site | 19 (43.2%) | | | | | | | | | | |
| History of trauma         | 4 (9.1%) | | | | | | | | | |
3.4 *Burkholderia cepacia* Specimens' Susceptibilities

The percentages of susceptibility to ceftazidime, tetracycline, trimethoprim-sulfamethoxazole and carbapenems were 84.1% (37/44), 54.5% (24/44), 63.2% (28/44) and 65.9% (29/44), respectively. Only eight isolates were tested for susceptibility to quinolones, and out of these; three were resistant. In addition, two out of the four specimens that were tested for susceptibility to piperacillin-tazobactam were resistant.

3.5 Patients’ Management

Antibiotic regimens were administered at our center depending on the clinician’s expertise, the patient’s comorbidities, and his clinical presentation. Once the cultures grew *B. cepacia*, the patients received directed therapy, with regimens including one or more of the following antibiotics: ceftazidime, quinolones, carbapenems, TMP-SMX, for an average duration of 23 days. Out of the 17 patients with bacteremia, 10 patients (10/17, 58.8%) were treated with a single antibiotic, 5 patients (5/17, 29.4%) received a combination therapy with 2 antibiotics, and only one patient (1/17, 5.9%) was treated with 3 antibiotics. Out of the 16 patients with SSTIs (including ulcers, wounds, and burns) as well as deep seated cysts and abscesses, 10 patients (10/16, 62.5%) received a single antibiotic, and 2 patients (2/16, 12.5%) were treated with a combination of two antibiotics. Out of the eight patients with osteomyelitis, four of them (4/8, 50%) were treated with a single antibiotic, three patients (3/8, 37.5%) received a combination therapy with two antibiotics, and one patient (1/8, 12.5%) was treated with three antibiotics. Among these patients, only two presented with neurological symptoms that required vertebral decompression by partial corpectomy. After the initiation of directed antibiotics, none of the eight patients with vertebral osteomyelitis required surgical debridement.

4 Discussion

Infections with Bcc outside the respiratory tract are uncommon. Our reported cases were mostly hospital acquired and had bacteremia, infected cysts and osteomyelitis. Of particular concern are the cases of osteomyelitis requiring prolonged antibiotic therapy.

The Infectious Diseases Society of America (IDSA) has recently published guidelines for the management of resistant Gram negative infections [13]. Unfortunately, no guidance on the proper management of *B. cepacia* was included. We have historically relied on the management of such infections based on clinical experience and published case reports. Few cases of Bcc osteomyelitis have been reported in the literature to date. Weinstein et al. reported a case of a 49-year-old female patient who presented 3 weeks after a rhinoplasty procedure, with *B. cepacia* osteomyelitis. Susceptibility testing revealed that the specimen was susceptible to ceftazidime, imipenem-cilastatin, levofloxacin, meropenem and piperacillin. The patient was treated with meropenem for 6 weeks with gradual resolution of her neck pain [14]. Another case of a 71-year-old previously healthy female farmer who presented with back pain and was found to have osteomyelitis at T5 level was reported by Hsieh et al. Initially, cefazolin and gentamicin were prescribed. She then developed neurologic signs necessitating transthoracic corpectomies. Intraoperative tissue culture confirmed *B. cepacia* infection which was susceptible to ceftazidime, meropenem, TMP-SMX, and levofloxacin. The source of the patient’s *B. cepacia* infection was thought to be her occupational environment. Her antibiotic therapy was changed to levofloxacin afterwards; however, she did not survive eventually due to septic shock [15]. In addition, Al Attia et al. reported a case of a 52-year-old presenting cranial vault osteomyelitis and multiple ring-enhancing frontal lobe brain abscesses. Cultured pus grew *B. cepacia* and he was treated with a combination of ceftazidime and piperacillin-tazobactam with marked improvement of his intracerebral and scalp lesions 3 weeks later [7]. Moreover, Lee et al. reported a case of an 80-year-old female patient who was found to have osteomyelitis of the sternum after a traumatic injury. Blood and pus cultures grew *B. cepacia* sensitive to ceftazidime, meropenem, TMP-SMX, and tigecycline. She was initially treated with ceftazidime followed by TMP-SMX and oral moxifloxacin for 3 months and improved initially. However, after having recurrence of the pus discharge, she received tigecycline, plus TMP-SMX with no documented recurrence thereafter [5].

Most of the reported patients in this series were Iraqi and Syrian despite the fact that the percentage of non-Lebanese patients at our hospital did not exceed 2–3% at any time during the study period. This raises the concern that countries at war might be at increased risk for such infections. Although there are no published data suggesting this to date, this needs to be further studied as we are currently witnessing more wars and conflicts in various parts of the world. Some other organisms such as *Acinetobacter* sp. had been previously associated with wars [16–20]. Recent data suggest that such organisms might be associated with heavy metals contamination [21]. Whether the same occurs with *B. cepacia* needs to be investigated. Most of the patients had risk factors such as malignancies, diabetes mellitus, recent steroids use, recent antibiotic use, including those not known to be active against Bcc, and recent surgical intervention at the site of the *B. cepacia* infection. The latter has most likely been related to contaminated solutions or other materials used intraoperatively as previously reported [8, 22].
reported sources of hospital-acquired Bcc infections include intravenous flush solutions, contaminated ultrasound gel, albuterol and nasal spray [6–8]. However, this was unlikely in our cases as we could not identify a cluster of cases.

There have been some variations in the sensitivities based on the type of susceptibility testing used. Though EUCAST does not recommend to test for Bcc susceptibility routinely in diagnostic microbiology laboratories because of poor reproducibility and correlation in all methods used, disk diffusion is recommended by CLSI, [23] and is the method adapted at AUBMC.

To date, there is still a lack of sufficient studies to guide therapy for Bcc infections outside the respiratory tract.

The reported cases of B. cepacia bacteremia, osteomyelitis or abscesses, all showed susceptibilities to ceftazidime. The majority showed susceptibility to carbapenem and TMP-SMX as well. Fewer reports revealed susceptibility to quinolones, piperacillin-tazobactam and tigecycline [14, 15]. One reported patient had a recurrent B. cepacia infection causing osteomyelitis and a sternal abscess that was successfully treated with tigecycline [14]. Similar to the literature, the majority of collected Bcc cultures from all sites of our case series were susceptible to ceftazidime, followed by carbapenems and TMP-SMX. B. cepacia tends to be more resistant to quinolones and piperacillin-tazobactam. Most of our patients were successfully treated with single and combination regimens. The durations of therapy was variable depending on the host, the site of infection and the rapidity of clinical response. Those with osteomyelitis received a prolonged course of therapy as is the case in the management of osteomyelitis due to other pathogens. Since the antimicrobial stewardship program (ASP) efforts started at AUBMC in 2004, all the patients were followed closely by the Infectious Diseases team and the ASP team to guide the clinicians on proper duration of therapy. This was correlated with a positive outcome of the patients. Our current series can expand on the limited published reports on infections with Bcc outside the respiratory tract. We expect and hope that the next update of the IDSA guidelines on management of osteomyelitis due to other pathogens. Since the antimicrobial stewardship program (ASP) efforts started at AUBMC in 2004, all the patients were followed closely by the Infectious Diseases team and the ASP team to guide the clinicians on proper duration of therapy. This was correlated with a positive outcome of the patients. Our current series can expand on the limited published reports on infections with Bcc outside the respiratory tract. We expect and hope that the next update of the IDSA guidelines on management of osteomyelitis due to other pathogens. Since the antimicrobial stewardship program (ASP) efforts started at AUBMC in 2004, all the patients were followed closely by the Infectious Diseases team and the ASP team to guide the clinicians on proper duration of therapy. This was correlated with a positive outcome of the patients. Our current series can expand on the limited published reports on infections with Bcc outside the respiratory tract. We expect and hope that the next update of the IDSA guidelines on management of osteomyelitis due to other pathogens. Since the antimicrobial stewardship program (ASP) efforts started at AUBMC in 2004, all the patients were followed closely by the Infectious Diseases team and the ASP team to guide the clinicians on proper duration of therapy. This was correlated with a positive outcome of the patients. Our current series can expand on the limited published reports on infections with Bcc outside the respiratory tract. We expect and hope that the next update of the IDSA guidelines on management of osteomyelitis due to other pathogens. Since the antimicrobial stewardship program (ASP) efforts started at AUBMC in 2004, all the patients were followed closely by the Infectious Diseases team and the ASP team to guide the clinicians on proper duration of therapy. This was correlated with a positive outcome of the patients. Our current series can expand on the limited published reports on infections with Bcc outside the respiratory tract. We expect and hope that the next update of the IDSA guidelines on management of osteomyelitis due to other pathogens. Since the antimicrobial stewardship program (ASP) efforts started at AUBMC in 2004, all the patients were followed closely by the Infectious Diseases team and the ASP team to guide the clinicians on proper duration of therapy. This was correlated with a positive outcome of the patients. Our current series can expand on the limited published reports on infections with Bcc outside the respiratory tract. We expect and hope that the next update of the IDSA guidelines on management of osteomyelitis due to other pathogens. Since the antimicrobial stewardship program (ASP) efforts started at AUBMC in 2004, all the patients were followed closely by the Infectious Diseases team and the ASP team to guide the clinicians on proper duration of therapy. This was correlated with a positive outcome of the patients. Our current series can expand on the limited published reports on infections with Bcc outside the respiratory tract. We expect and hope that the next update of the IDSA guidelines on management of osteomyelitis due to other pathogens. Since the antimicrobial stewardship program (ASP) efforts started at AUBMC in 2004, all the patients were followed closely by the Infectious Diseases team and the ASP team to guide the clinicians on proper duration of therapy. This was correlated with a positive outcome of the patients. Our current series can expand on the limited published reports on infections with Bcc outside the respiratory tract. We expect and hope that the next update of the IDSA guidelines on management of osteomyelitis due to other pathogens. Since the antimicrobial stewardship program (ASP) efforts started at AUBMC in 2004, all the patients were followed closely by the Infectious Diseases team and the ASP team to guide the clinicians on proper duration of therapy. This was correlated with a positive outcome of the patients. Our current series can expand on the limited published reports on infections with Bcc outside the respiratory tract. We expect and hope that the next update of the IDSA guidelines on management of osteomyelitis due to other pathogens. Since the antimicrobial stewardship program (ASP) efforts started at AUBMC in 2004, all the patients were followed closely by the Infectious Diseases team and the ASP team to guide the clinicians on proper duration of therapy. This was correlated with a positive outcome of the patients. Our current series can expand on the limited published reports on infections with Bcc outside the respiratory tract. We expect and hope that the next update of the IDSA guidelines on management of osteomyelitis due to other pathogens.

5 Conclusion

B. cepacia infections whether bacteremia, SSTIs, abscesses or osteomyelitis were noted to be more common at our medical center as hospital-acquired infections particularly in Iraqi and Syrian patients. In addition, many of the patients had one or more immunosuppressive conditions. This raises the concern that patients in countries at war and with immunosuppressive conditions might be at increased risk for such infections. Empiric treatment for such pathogens might be needed in the right clinical scenario. There is a need to study the epidemiology of this pathogen in areas of wars and conflicts. Our results of antibiotic susceptibilities were consistent with the literature, showing that the majority of isolates are sensitive to ceftazidime, followed by carbapenems then TMP-SMX. Although B. cepacia is a resistant bacterium, almost all our patients were successfully treated under the guidance of an ASP. Future international guidelines are needed to guide clinicians for optimal therapy.

Author Contributions HH, RK, NY and JH collected the data. JH performed the analysis. RK and HH drafted the manuscript. SK and SH revised the manuscript. All authors read and approved the manuscript.

Funding This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.

Data Availability The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.

Declarations

Conflict of Interest The authors have no competing interests to declare that are relevant to the content of this article.

Ethical Approval Approval was obtained from the American University of Beirut institutional review board.

Informed Consent This is a retrospective chart review study, informed consent was not provided.

Consent for Publication Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Hassan AA, Coutinho CP, Sá-Correia I. Burkholderia cepacia complex species differ in the frequency of variation of the lipopolysaccharide O-antigen expression during cystic fibrosis chronic respiratory infection. Front Cell Infect Microbiol. 2019. https://doi.org/10.3389/fcimb.2019.00273.

2. Drevinek P, Mahenthiralingam E. Burkholderia cenoceacapa in cystic fibrosis: epidemiology and molecular mechanisms of virulence. Clin Microbiol Infect. 2010;16(7):821–30.
3. Isles A, Maclusky I, Corey M, Gold R, Prober C, Fleming P, et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr. 1984;104(2):206–10.

4. Tablan OC, Martone WJ, Doershuk CF, Stern RC, Thomassen MJ, Klinger JD, et al. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk Factors Outcomes Chest. 1987;91(4):527–32.

5. CLSI. Performance standards for antimicrobial susceptibility testing. 30th edition. CLSI guideline M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.

6. Held MR, Begier EM, Beardsley DS, Browne FA, Martinello RA, Baltimore RS, et al. Life-threatening sepsis caused by Burkholderia cepacia from contaminated intravenous flush solutions prepared by a compounding pharmacy in another state. Pediatrics. 2006;118(1):e212-215.

7. Jacobson M, Wray R, Kovach D, Henry D, Speert D, Matlow A. Sustained endemicity of Burkholderia cepacia complex in a pediatric institution, associated with contaminated ultrasound gel. Infect Control Hosp Epidemiol. 2006;27(5):1346–53.

8. Estivariz CF, Bhatti LI, Pati R, Jensen B, Arduino MJ, Jernigan D, et al. An outbreak of Burkholderia cepacia associated with contamination of albuterol and nasal spray. Chest. 2004;120(4):140–4.

9. Lau T, Fang C, Leung F. Assessment of postoperative short-term and long-term mortality risk in Chinese geriatric patients for hip fracture using the Charlson comorbidity score. Hong Kong Med J. 2015. https://doi.org/10.12809/hkmj154451.

10. Bell DB, Pretorius E. To what extent are the terminal stages of sepsis, septic shock, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome actually driven by a prion/amyloid form of fibrin? Semin Thromb Hemost. 2018;44(3):224–38.

11. Tamma PD, Atitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious diseases society of America guidance on the treatment of extended-spectrum β-lactamase producing enterobacteriaceae (ESBL–E), carbapenem-resistant enterobacteriaceae (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P aeruginosa). Clin Infect Dis. 2021;72(7):e169–83.

12. Lee W-S, Hsieh T-C, Ou T-Y, Chen F-L, Yu F-L, Jean S-S, et al. Successful salvage therapy with tigecycline and trimethoprim-sulfamethoxazole for recurrent osteomyelitis caused by Burkholderia cepacia. J Microbiol Immunol Infect. 2017;50(1):123–4.

13. Hsieh C-T, Hsu S-K, Chang C-J. Thoracic vertebral osteomyelitis caused by Burkholderia cepacia in an immunocompetent adult. Surg Infect (Larchmt). 2013;14(5):476–9.

14. Higgins PG, Hagen RM, Podbielski A, Frickmann H, Warnke P. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii isolated from war-injured patients from the eastern Ukraine. Antibiotics (Basel). 2020;9(9):579.

15. Salloum T, Tannous E, Alousi S, Arabaghian H, Rafei R, Hamze M, et al. Genomic mapping of ST85 bladNM-1 and blaoXa-94 producing Acinetobacter baumannii isolates from Syrian civil war victims. Int J Infect Dis. 2018;74:100–8.

16. Dallo SF, Weitao T. Insights into Acinetobacter war-wound infections, biofilms, and control. Adv Skin Wound Care. 2010;23(4):169–74.

17. Truppa C, Aboshehada MN. Antimicrobial resistance among GLASS pathogens in conflict and non-conflict affected settings in the Middle East: a systematic review. BMC Infect Dis. 2020;20(1):936.

18. Kondratiuk V, Jones BT, Kovalchuk V, Kovalenko I, Ganiuk V, Kondratiuk O, et al. Phenotypic and genotypic characterization of antibiotic resistance in military hospital-associated bacteria from war injuries in the Eastern Ukraine conflict between 2014 and 2020. J Hosp Infect. 2021;112:69–76.

19. Bazzi W, Abou Fayad AG, Nasser A, Haraoui L-P, Dewachi O, Abou-Sitta G, et al. Heavy metal toxicity in armed conflicts potentiates AMR in A. baumannii by selecting for antibiotic and heavy metal co-resistance mechanisms. Front Microbiol. 2020;11:68.

20. Al Attia HM, Qureshi RA, El Hag IA. Skull osteomyelitis and multiple brain abscesses. Postgrad Med J. 2000;76(892):124.

21. Wootton M, Davies L, Pitman K, Howe RA. Evaluation of susceptibility testing methods for Burkholderia cepacia complex: a comparison of broth microdilution, agar dilution, gradient strip and EUCAST disc diffusion. Clin Microbiol Infect. 2020. https://doi.org/10.1016/j.cmi.2020.11.012.